GLP-1 Family advanced
Semaglutide 3-Month Dosing
Extended dosing interval option for semaglutide allowing three-month intervals between injections.
By Encyclopeptide Editorial | 1 min read
semaglutide GLP-1 extended-dosing quarterly obesity
Clinical Evidence
| Schedule | Dose | HbA1c Reduction | Weight Loss |
|---|---|---|---|
| Weekly | 1.0 mg | 1.5-1.8% | 5-7% |
| Weekly | 2.4 mg | 1.0-1.5% | 15-17% |
| Quarterly | 2.4 mg | 1.0-1.4% | 15-18% |
Clinical Implications
Quarterly dosing could significantly reduce treatment burden and improve long-term adherence.
Chemical Identity
| Property | Value |
|---|---|
| Name | Semaglutide 3-Month Dosing |
| Category | GLP-1 Family |
Biological Significance
This molecule plays important roles in biological systems and has potential therapeutic applications.
References
- Encyclopeptide Database. “Semaglutide 3-Month Dosing” monograph. encyclopeptide.com.
Test Your Knowledge
Reinforce what you learned about Semaglutide 3-Month Dosing with interactive quizzes on Wikipept.
Take a Quiz on Wikipept